About Us | Contact Us | Editorial Board | About Haymarket Media

RSS | Login | Register

The more we know about our visitors, the easier it will be for us to publish everything you want to see.

Email*

Password*

Keep me logged in Forgot your password?

Email*

HYDREA

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare HYDREA to:

Generic Name for HYDREA

Hydroxyurea 500mg; caps.

Legal Classification:

Pharmacological Class for HYDREA

Substituted urea.

Manufacturer of HYDREA

Bristol-Myers Squibb

Indications for HYDREA

Recurrent metastatic or inoperable ovarian carcinoma.

Other Indications for HYDREA

Head and neck cancer

Leukemias, lymphomas, and other hematologic cancers

Melanoma and other skin cancers

Adult dose for HYDREA

See literature. Intermittant therapy for solid tumors: 80mg/kg as single dose every 3^rd day. Continuous therapy for solid tumors: 20–30mg/kg/day as single dose. Renal impairment: reduce dose.

Children's dosing for HYDREA

Not recommended.

Contraindications for HYDREA

Marked bone marrow depression.

Warnings/Precautions for HYDREA

Previous irradiation therapy or chemotherapy. Correct anemia before starting. Monitor hematologic, renal, hepatic function before and during treatment. Marked renal dysfunction. Myeloproliferative disorders; discontinue if cutaneous vasculitic ulcerations develop and use alternative agents. Elderly. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

Interactions for HYDREA

Avoid concomitant didanosine, with or without stavudine, or other antiretrovirals (may cause pancreatitis [monitor], fatal hepatotoxicity, peripheral neuropathy). Myelosuppressives potentiate antineoplastic effect. May antagonize antigout agents. Increased risk of vasculitic toxicities with interferon therapy. May cause falsely elevated urease, uricase, lactate dehydrogenase.

Adverse Reactions for HYDREA

Leukopenia, anemia, erythrocytic abnormalities, thrombocytopenia, GI upset, rash, erythema, fever, CNS effects, temporary renal impairment, acute pulmonary reactions, secondary leukemias, skin cancer.

Notes for HYDREA

Wear disposable gloves when handling caps or bottle.

How is HYDREA supplied?

Caps—100

Related Disease:

Cancer, head and neck

Cancer, ovarian

Leukemia, chronic myelocytic

Melanoma

Data provided by the Monthly Prescribing Reference (MPR) Hematology/Oncology Edition.

Adjuvant Radiochemotherapy Has Lasting Benefit in Gastric Cancer

May 18, 2012

Patients with gastric cancer who undergo resection show survival benefit 10 years later.

Fertility-Related Information Urgently Needed for Female Patients with Cancer

Debra Hughes May 18, 2012

Young adult males and females with cancer receive vastly different amounts of fertility-related and fertility preservation information.

STAT3 Mutations ID'd in Rare Lymphoproliferative Disorder

May 18, 2012

Four specific mutations in SH2 domain seen in T-cell large granular lymphocytic leukemia.

Genetic Profiling Improves Prognosis of Uveal Melanoma

James Netterwald, PhD May 18, 2012

Gene expression profiling (GEP) and chromosomal analysis show prognostic value in patients with uveal melanoma.

Bisphosphonates Cut Skeletal Morbidity in Multiple Myeloma

May 18, 2012

Zoledronate superior to placebo or etidronate for improving overall survival.

Bleomycin

Oncology > Respiratory and thoracic cancers

Bleomycin 15units/vial, 30units/vial; lyophilized pwd for IM, IV, SC, or intrapleural administration after reconstitution.

Floxuridine

Oncology > Colorectal and other GI cancers

Floxuridine 500mg/vial; lyophilized pwd for intra-arterial infusion after reconstitution and dilution.

MENEST

Oncology > Prostate and other male cancers

Esterified estrogens 0.3mg, 0.625mg, 1.25mg, 2.5mg; tabs.

THYROGEN

Oncology > Pancreatic, thyroid, and other endocrine cancers

Thyrotropin alfa 1.1mg/vial; lyophilized pwd for IM inj after reconstitution; contains mannitol.

TOPOSAR

Oncology > Prostate and other male cancers

Etoposide 20mg/mL; soln for IV infusion; contains dehydrated alcohol 33.2%, polysorbate 80.

Oncology > Cytoprotective and supportive care agents

Bisphosphonates (eg, Aredia, Zometa) may inhibit the activation of cancer-associated proteins through the suppression of geranyl-geranylation and farnesylation or inhibit ...
more »

'Teachable Moments' for Smoking Cessation in Patients Diagnosed with Cancer Underutilized

Debra Hughes February 16, 2012

Less than one-fifth (18.1%) of healthcare providers reported high levels of confidence in their ability to counsel patients with cancer who smoke to quit smoking, a survey published in The Oncologist online February 14 has found.